DG 051

Drug Profile

DG 051

Alternative Names: DG-051

Latest Information Update: 30 Jan 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator deCODE genetics; Saga Investments
  • Developer deCODE genetics
  • Class Cardiovascular therapies; Pyrrolidines; Small molecules
  • Mechanism of Action Leukotriene A4 hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Myocardial infarction

Most Recent Events

  • 31 Dec 2012 deCODE genetics has been acquired by Amgen
  • 09 Jan 2008 Adverse events data from a phase IIa trial in myocardial infarction released by deCODE
  • 10 Oct 2007 Phase-II clinical trials in Myocardial infarction in Iceland (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top